About Exscientia
Recursion is a pioneering TechBio company founded over a decade ago on the revolutionary idea of using cellular imaging and artificial intelligence to decode biology and transform drug discovery. The company has built the Recursion Operating System (Recursion OS), an advanced AI-driven drug discovery and development platform that leverages one of the largest fit-for-purpose proprietary biological and chemical datasets in the world—over 50 petabytes spanning phenomics, transcriptomics, proteomics, ADME, and de-identified patient data. Recursion's mission is to radically improve lives by addressing the massive 90% failure rate of traditional drug discovery through novel insights and precision design. The company's automated wet lab utilizes robotics and computer vision to capture millions of cell experiments per week, feeding results back into the platform in a continuously improving feedback loop. This approach has demonstrated significant improvements in speed, efficiency, and reduced costs from hit identification to IND-enabling studies compared to traditional pharmaceutical company averages. The company has developed an advanced pipeline of potential first-in-class and best-in-class treatments targeting conditions with high unmet need, including aggressive cancers such as advanced solid tumors, B-cell malignancies, and lymphomas, as well as rare diseases like familial adenomatous polyposis and hypophosphatasia. Multiple programs are currently in clinical trials, including the TUPELO, ELUCIDATE, DAHLIA, EXCELERIZE, and ENLYGHT studies. Recursion partners with pharmaceutical industry leaders and technology giants like NVIDIA, with whom they built BioHive-2, biopharma's most powerful supercomputer. The company is headquartered in Salt Lake City, Utah, and is a proud founding member of BioHive, the fastest-growing life sciences community in the nation.
Mission & Story
Mission
Decoding biology to radically improve lives
Founding Story
Recursion was founded more than a decade ago on the idea that we could take images of cells and use these images to train artificial intelligence to understand the vast unknown biological space – the cellular disruptions driving disease – to use AI-drug discovery to reduce the massive 90% failure rate of traditional drug discovery.
Clinical Focus
Medical conditions and clinical areas addressed by Exscientia.
Who It Serves
Milestones & Awards
Recent Milestones
First patient dosed in Phase 1 clinical study of REC-3565 for B-cell lymphomas. Positive Phase 1b/2 results from ongoing REC-4881 TUPELO trial. Built BioHive-2 supercomputer with NVIDIA.
Awards & Recognition
Founding member of BioHive, the fastest growing life sciences community in the nation
Key Partnerships
Company Details
- Headquarters
- Salt Lake City, UT, USA
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 64 →
A2A Pharmaceuticals
AI-driven pharmaceutical company focused on discovering and developing novel drug candidates using computational biology and machine learning.
AbCellera
AbCellera uses AI and machine learning to discover and develop antibody-based therapeutics and vaccines.
Absci
Absci uses AI-powered computational biology and machine learning to accelerate drug discovery and optimize therapeutic proteins and antibodies.
Adaptyv Bio
11-50 employees
Adaptyv Bio operates the world's fastest protein validation lab, providing automated experimental testing services for AI-designed proteins. The company enables protein engineers to validate binding, expression, and thermostability of novel protein designs through a fully automated platform with 3-week turnaround times.
Aitia
Aitia is a drug discovery and development company leveraging AI and computational biology to identify novel therapeutic targets and accelerate drug development.
Anagenex
Anagenex is a biotechnology company focused on drug discovery and development. The company appears to operate in the pharmaceutical research space, though specific details about their technology platform, therapeutic areas, and target markets are not available from the provided content.
Aqemia
Aqemia is a drug discovery company advancing next-generation medicines using generative AI and deep physics. The company combines AI-augmented discovery with computational chemistry to develop novel therapeutics at scale.
Arctoris
51-200 employees
Arctoris is a Partnership Research Organisation (PRO) providing automated wet lab biology R&D and data generation services for biotech, techbio, and pharma companies through its Ulysses® robotic platform.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.